These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 8815752

  • 1. Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia.
    Kattan MW, Inoue Y, Giles FJ, Talpaz M, Ozer H, Guilhot F, Zuffa E, Huber SL, Beck JR.
    Ann Intern Med; 1996 Oct 01; 125(7):541-8. PubMed ID: 8815752
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of interferon alfa in chronic myelogenous leukemia.
    Liberato NL, Quaglini S, Barosi G.
    J Clin Oncol; 1997 Jul 01; 15(7):2673-82. PubMed ID: 9215840
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis.
    Dalziel K, Round A, Stein K, Garside R, Price A.
    Health Technol Assess; 2004 Jul 01; 8(28):iii, 1-120. PubMed ID: 15245690
    [Abstract] [Full Text] [Related]

  • 4. Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia.
    Beck JR, Guilhot J, Giles FJ, Aoki N, Wirt DP, Guilhot F.
    Leuk Lymphoma; 2001 Mar 01; 41(1-2):117-24. PubMed ID: 11342363
    [Abstract] [Full Text] [Related]

  • 5. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
    Warren E, Ward S, Gordois A, Scuffham P.
    Clin Ther; 2004 Nov 01; 26(11):1924-33. PubMed ID: 15639704
    [Abstract] [Full Text] [Related]

  • 6. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia.
    Dalziel K, Round A, Garside R, Stein K.
    Pharmacoeconomics; 2005 Nov 01; 23(5):515-26. PubMed ID: 15896102
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Treatment of chronic myeloid leukemia using alpha-interferon and hydroxyurea. Study of 30 cases].
    Nese M, de Bellis R, Urtiarte R, Di Landro J.
    Sangre (Barc); 1994 Jun 01; 39(3):183-6. PubMed ID: 7940047
    [Abstract] [Full Text] [Related]

  • 9. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.
    Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Löffler H, Hochhaus A, Heinze B.
    Blood; 1994 Dec 15; 84(12):4064-77. PubMed ID: 7994025
    [Abstract] [Full Text] [Related]

  • 10. Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis.
    Lee SJ, Kuntz KM, Horowitz MM, McGlave PB, Goldman JM, Sobocinski KA, Hegland J, Kollman C, Parsons SK, Weinstein MC, Weeks JC, Antin JH.
    Ann Intern Med; 1997 Dec 15; 127(12):1080-8. PubMed ID: 9412310
    [Abstract] [Full Text] [Related]

  • 11. Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis.
    Sheng G, Chen S, Dong C, Zhang R, Miao M, Wu D, Tan SC, Liu C, Xiong T.
    J Med Econ; 2017 Apr 15; 20(4):371-381. PubMed ID: 27936995
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of interferon in chronic myeloid leukaemia: analysis of four clinical studies.
    Messori A.
    Ann Oncol; 1998 Apr 15; 9(4):389-96. PubMed ID: 9636829
    [Abstract] [Full Text] [Related]

  • 13. [Treatment with interferon alfa-2a in the chronic phase of Philadelphia-positive chronic myeloid leukemia].
    Steegmann JL, Lavilla E, Somolinos N, Pérez-Sánchez M, Lamana M, Olmeda F, Cámara R, Arranz R, Ferro MT, Fernández-Rañada JM.
    Sangre (Barc); 1992 Oct 15; 37(5):375-81. PubMed ID: 1293778
    [Abstract] [Full Text] [Related]

  • 14. Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.
    Li N, Yang X, Fan L, Totev T, Guerin A, Chen L, Bhattacharyya S, Joseph G.
    J Med Econ; 2017 Apr 15; 20(4):328-336. PubMed ID: 27841717
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cost-Effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma.
    Wirt DP, Giles FJ, Oken MM, Solal-Celigny P, Beck JR.
    Leuk Lymphoma; 2001 Feb 15; 40(5-6):565-79. PubMed ID: 11426529
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.
    Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH, Arthur DD, Powell B, Gottlieb A, Peterson BA, Rai K, Testa JR, LeBeau M, Tantravahi R, Bloomfield CD.
    Blood; 1993 Nov 15; 82(10):2975-84. PubMed ID: 8219189
    [Abstract] [Full Text] [Related]

  • 19. A prospective comparison of alpha-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.
    Haematologica; 1992 Nov 15; 77(3):204-14. PubMed ID: 1427426
    [Abstract] [Full Text] [Related]

  • 20. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.
    Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgeroth G, Maywald O, Hasford J, Reiter A, Hossfeld DK, Kolb HJ, Löffler H, Pralle H, Queisser W, Griesshammer M, Nerl C, Kuse R, Tobler A, Eimermacher H, Tichelli A, Aul C, Wilhelm M, Fischer JT, Perker M, Scheid C, Schenk M, Weiss J, Meier CR, Kremers S, Labedzki L, Schmeiser T, Lohrmann HP, Heimpel H, German CML-Study Group.
    Leukemia; 2003 Aug 15; 17(8):1529-37. PubMed ID: 12886239
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.